"Cardiotoxicity" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Damage to the heart or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.
| Descriptor ID |
D066126
|
| MeSH Number(s) |
C23.550.161 C25.100.389 C26.733.266 G01.750.748.500.266
|
| Concept/Terms |
Cardiotoxicity- Cardiotoxicity
- Cardiotoxicities
- Cardiac Toxicity
- Cardiac Toxicities
- Toxicities, Cardiac
- Toxicity, Cardiac
|
Below are MeSH descriptors whose meaning is more general than "Cardiotoxicity".
Below are MeSH descriptors whose meaning is more specific than "Cardiotoxicity".
This graph shows the total number of publications written about "Cardiotoxicity" by people in this website by year, and whether "Cardiotoxicity" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cardiotoxicity" by people in Profiles.
-
Structural investigation on the selective COX-2 inhibitors mediated cardiotoxicity: A review. Life Sci. 2020 Jun 15; 251:117631.
-
Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. Cancer Chemother Pharmacol. 2019 04; 83(4):717-726.
-
Design and development of PEGylated liposomal formulation of HER2 blocker Lapatinib for enhanced anticancer activity and diminished cardiotoxicity. Biochem Biophys Res Commun. 2018 09 05; 503(2):677-683.
-
Immunization of Mice with Anthrax Protective Antigen Limits Cardiotoxicity but Not Hepatotoxicity Following Lethal Toxin Challenge. Toxins (Basel). 2015 Jun 25; 7(7):2371-84.
-
A Phase I cardiac safety and pharmacokinetic study of tivozanib hydrochloride in patients with advanced solid tumors. Clin Pharmacol Drug Dev. 2014 07; 3(4):284-9.